KLACID Hp

Страна: Малайзія

мова: англійська

Джерело: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Активний інгредієнт:

AMOXYCILLIN; CLARITHROMYCIN; PANTOPRAZOLE

Доступна з:

ABBOTT LABORATORIES (M) SDN. BHD.

ІПН (Міжнародна Ім'я):

AMOXYCILLIN; CLARITHROMYCIN; PANTOPRAZOLE

Одиниць в упаковці:

28 Tablets; 14 Tablets

Виробник:

ZUELLIG PHARMA SDN BHD

Характеристики продукта

PRODUCT INFORMATION
This document refers to the use of pantoprazole, clarithromycin and
amoxycillin in combination for the treatment of patients with peptic
ulcer disease. The components of this therapy are frequently used to
treat other conditions. For information about the treatment of
conditions other than peptic ulcer disease, refer to full Product
Information for the appropriate component.
NAME OF DRUG
KLACID
®
Hp is a combination pack containing Klacid
®
(active ingredient clarithromycin) 500mg tablet, Controloc (active
ingredient
pantoprazole sodium sesquihydrate 45.1mg which is equivalent to
pantoprazole 40mg) 40mg tablet, and Ospamox (active ingredient
amoxicillin) 1gm tablet.
DESCRIPTION
KLACID
®
pale yellow ovaloid film-coated tablet.
CONTROLOC yellow, oval, biconvex enteric-coated tablets with a white
to off-white core printed with brown ink, on one side: P40.
OSPAMOX white to cream coloured tablet, oblong, biconvex, with break
scores on both sides.
PHARMACOLOGY
KLACID
®
Hp Helicobacter pylori is a spiral, flagellated, Gram-negative rod,
primarily colonising the antrum of the stomach, it
congregates at, and around intercellular junctions. The natural
habitat of H.pylori is the gastric mucosa, where the bacterium
attaches itself via adhesion pedestals. H.pylori is associated with
duodenal and gastric ulcer disease in about 95% and 70% of
patients, respectively. H.pylori is the major factor in the
development of gastritis and ulcers in such patients. Eradication of
H.pylori
is associated with reduced peptic ulcer recurrence. Eradication of
H.pylori is therefore appropriate therapy in most patients with
duodenal and gastric ulcer where the latter is not caused by
non-steriodal anti-inflammatory drug (NSAID) ingestion. Eradication of
H.pylori was achieved in approximately 95% of patients following
therapy with clarithromycin, pantoprazole and amoxycillin.
KLACID
®
Clarithromycin is active in vitro and in vivo against H.pylori.
Clarithromycin exerts its antibacterial action by binding to
the 50s ribos